Aligos Therapeutics (NASDAQ:ALGS) Trading Up 4.2% – Should You Buy?

Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) traded up 4.2% during trading on Tuesday . The company traded as high as $4.37 and last traded at $4.25. 87,495 shares were traded during mid-day trading, a decline of 72% from the average daily volume of 308,959 shares. The stock had previously closed at $4.08.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Weiss Ratings raised shares of Aligos Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 10th. Cantor Fitzgerald reissued an “overweight” rating on shares of Aligos Therapeutics in a research report on Friday, May 29th. Wall Street Zen upgraded Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, May 17th. Finally, Lake Street Capital began coverage on Aligos Therapeutics in a research report on Thursday, May 28th. They issued a “buy” rating and a $45.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $38.50.

Aligos Therapeutics Stock Up 4.2%

The firm has a 50 day moving average price of $5.48 and a two-hundred day moving average price of $6.64. The company has a market capitalization of $26.31 million, a price-to-earnings ratio of -0.49 and a beta of 2.26.

Aligos Therapeutics (NASDAQ:ALGS) last released its quarterly earnings results on Thursday, May 7th. The company reported ($2.21) EPS for the quarter, topping the consensus estimate of ($2.29) by $0.08. The business had revenue of $2.83 million for the quarter, compared to analysts’ expectations of $0.25 million. Aligos Therapeutics had a negative return on equity of 139.47% and a negative net margin of 1,919.68%. Analysts predict that Aligos Therapeutics, Inc. will post -7.47 earnings per share for the current year.

Hedge Funds Weigh In On Aligos Therapeutics

A number of institutional investors have recently made changes to their positions in ALGS. Rockefeller Capital Management L.P. boosted its stake in shares of Aligos Therapeutics by 900.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock valued at $93,000 after buying an additional 9,000 shares during the last quarter. Susquehanna International Group LLP bought a new stake in shares of Aligos Therapeutics in the third quarter worth $99,000. XTX Topco Ltd bought a new stake in shares of Aligos Therapeutics in the second quarter worth $100,000. HRT Financial LP acquired a new stake in Aligos Therapeutics in the fourth quarter valued at $106,000. Finally, DRW Securities LLC acquired a new stake in Aligos Therapeutics in the fourth quarter valued at $111,000. 60.43% of the stock is owned by institutional investors and hedge funds.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.